New pill shows promise against tough blood cancers in early trial
NCT ID NCT04167917
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 29 times
Summary
This early-phase study tested an oral drug called NTX-301 in 22 adults with blood cancers (MDS, AML, or CMML) that had not responded to prior treatment. The main goal was to check safety and find the right dose. Researchers also looked for signs that the drug could control the disease, such as reducing cancer cells or improving blood counts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
University of Alabama at Birmingham
Birmingham, Alabama, 35294, United States
Conditions
Explore the condition pages connected to this study.